Targeting the incretin system in obesity and type 2 diabetes mellitus Nature Reviews Endocrinology In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Cagrilintide: The Peptide That Makes You Forget About Food. I call it the silence between cravings. Cagrilintide is a long acting amylin analog which means it works alongside leptin and GLP 1 to Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment Journal of Medicinal Chemistry Understanding Cagrilintide: Benefits and Uses TikTok